ArticleFrontiers in public health2025
Availability, price and affordability of anticancer medicines in Jiangsu Province, China: a cross-sectional survey study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate anticancer medicines' availability, price and affordability in nine prefecture-level cities, Jiangsu Province. Methods: Based on the standard methods recommended by the World Health Organization (WHO) and the Health Action International (HAI), a cross-sectional survey was performed to collect information about 24 essential anticancer medicines (EAMs) and 17 innovative anticancer medicines (IAMs) in hospitals and 45 community pharmacies in Jiangsu Province from July to November 2021. Results: In general, the availability of EAMs during the study period was higher than that of IAMs, and the availability of the Lowest-priced generics (LPGs) was higher than that of the originator brands (OBs). Anticancer medicines in hospitals were more available than those in community pharmacies. Specifically, the availability of anticancer medicines positively correlated with different cities' economic status. However, there were no significant changes in the availability of IAMs among different cities. The median price ratio (MPR) value of OBs was greater than that of LPGs, and both were greater than one. There were no significant changes in the MPR value of EAMs among different economic regions ( Conclusion: The availability of anticancer medicines in community pharmacies was low, especially in intravenous anticancer preparations. The Chinese government formulated a dual-channel policy to improve the availability of anticancer medicines in community pharmacies. However, implementing the dual-channel policy required the effective interaction and cooperation of the hospitals, community pharmacies, medical insurance, and other departments. The price of IAMs was still the main obstacle to receiving treatment for cancer patients; therefore, the government should further optimize the price of IAMs through various strategies to achieve a reasonable price. Expanding the coverage of EAMs was conducive to improving treatment affordability for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.